Table 3 Base case results by health states, Nivolumab
Base Case Results | Nivolumab |
|---|---|
Life Years, discounted (rate: 3%) | |
Relapse Free Survival | 9.48 |
Locoregional progression | 0.76 |
Distant metastasis | 1.21 |
Total LY | 11.44 |
QALY, discounted (rate: 3%) | |
Relapse Free Survival | 8.23 |
Locoregional progression | 0.66 |
Distant metastasis | 0.82 |
Total QALY | 9.71 |
Lifetime costs (T€, discounted, rate: 3%) | |
Treatment | 76.7 |
Relapse Free Survival | 3.5 |
Locoregional progression | 0.19 |
Distant metastasis | 37.6 |
Total | 118.1 |